ALZAMEND NEURO INC (ALZN)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$1.55+1.31%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · ALZN
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Elevated risk of a next-quarter earnings miss: this name is a smaller-cap name (higher miss base rate) and is on a run of consecutive earnings misses. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
ALZN — litigation filed
Dated 2026-09-29
Regulation FD Disclosure. On September 29, 2026, Dr. Ovidiu C. Andronesi, principal investigator on Alzamend Neuro, Inc.’s Phase 1/2A Clinical Trial, Director of Multinuclear MRI, Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, and Associate Professor of Radiology at Harvard Medical School, will presented at the International Society for MR Radiographers & Technologists (ISMRT) Conference. A copy of the presentation, which is furnished herewith…
Why it matters: The company disclosed that it did not meet Nasdaq’s board independence rule. A cure or further listing action would change this risk.
Watch forA company filing says Nasdaq confirmed the board now meets the majority independent rule. Or, Nasdaq granted an extension to fix it.
Also watch forA company filing reports a Nasdaq delisting notice. Or, it says the company still fails the rule after its cure deadline.
Why it matters: Equity raises can fund drug work, but they can also dilute current shareholders. The inputs flag capital raising as an item to watch.
Watch forAn 8-K or company release reports an equity raise, its size, and how the funds will be used. This may include support for AL001 trials.
Also watch forThe next earnings report or filing says the company has funded planned AL001 work without a new share offering.
Why it matters: The first study found only a small, non-significant trend in brain lithium levels. Patient results will test whether that trend holds.
Watch forThe company or study team reports patient results. AL001 leads to more lithium in the brain than lithium carbonate. The difference is significant.
Also watch forPatient results show AL001 does not have higher brain lithium exposure. Or, results significantly favor lithium carbonate.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$226 on $10,000 · ±2.3% | How much price usually moves either way. |
| Bad day | $669 loss on $10,000 · 6.7% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,637 loss on $10,000 · 66.4% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.